Efficacy of the PARP inhibitor (PI) ABT-888 (veliparib [vel]) either with carboplatin (carb) or as a single agent followed by post-progression therapy in combination with carb in patients (pts) with BRCA1- or BRCA2- (BRCA)-associated metastatic breast cancer (MBC).
暂无分享,去创建一个
A. Chen | D. Gandara | M. Goetz | J. Sparano | R. Nanda | B. Arun | T. Moynihan | P. Frankel | H. Chew | J. Weitzel | G. Somlo | J. Mortimer | L. Vahdat | A. Hurria | H. Harvey | Cynthia X. Ma | T. Luu | Agustin A. Garcia | L. Cream | T. Cigler